Abstract: The present invention relates to the use of at least one tetrafunctional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.

Abstract: The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.

Abstract: The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.

Abstract: The present invention relates to a use of at least one glycosylated tetrafunctional amphiphilic block copolymer, as immune adjuvant.

Abstract: The present invention relates to a use of at least one glycosylated tetrafunctional amphiphilic block copolymer, as immune adjuvant.

Abstract: A stabilized multimodular assembly for intracellular delivery comprising a complex of at least one cationic transfection agent and of at least one negatively charged macromolecule, wherein the complex has a theoretical charge ratio ranging from about 0 to about 4, and an efficient amount of at least one amphiphilic block co-polymer acting as a steric colloidal stabilizer with respect to the complex, the block co-polymer having hydrophilic and hydrophobic blocks wherein at least one hydrophilic block is conjugated with at least one targeting ligand.

Abstract: A pharmaceutical composition, including at least one nucleic acid, a Tyrode's medium having 140 mM NaC1, 6 mM KC1, 3 mM CaC12, 2 mM MgC12, 10 mM Hepes, pH 7.4, and 10 mM glucose; and a tetrafunctional copolymer of formula (I): where x and y represent, independently of one another, an integer of between 1 and 500, the tetrafunctional copolymer is in a form of a mineral salt wherein said tetrafunctional copolymer is in a cationic form. The compound of formula (I) has a molecular weight of between 1,000 and 25,000 g/mol and an EO/PO ratio of 0.8 to 1.2.

Abstract: A stabilized multimodular assembly for intracellular delivery comprising a complex of at least one cationic transfection agent and of at least one negatively charged macromolecule, wherein the complex has a theoretical charge ratio ranging from about 0 to about 4, and an efficient amount of at least one amphiphilic block co-polymer acting as a steric colloidal stabilizer with respect to the complex, the block co-polymer having hydrophilic and hydrophobic blocks wherein at least one hydrophilic block is conjugated with at least one targeting ligand.

Abstract: A pharmaceutical composition which combines a tetrafunctional copolymer with a nucleic acid, said copolymer having formula I (namely a poloxamine), and preferably taking the form of one of the cationic mineral or organic salts thereof. The composition can be used to improve in vivo gene transfer.

Abstract: The invention relates to a pharmaceutical composition which combines a tetrafunctional copolymer with a nucleic acid, said copolymer having formula I (namely a poloxamine), and preferably taking the form of one of the cationic mineral or organic salts thereof. The inventive composition can be used to improve in vivo gene transfer.

Abstract: The present invention relates to a composition comprising a siRNA and a transfecting compound consisting of an aminoglycoside of the class of 4,5-disubstituted 2-deoxystreptamine ring linked via a spacer molecule to a lipid moiety of formula —(R1)R2 wherein R1 and R2 represent, independently of one another, a hydrogen atom or a fatty aliphatic chain or R1 or R2 is absent, with the proviso that at least one of R1 and R2 represents a fatty aliphatic chain; or —OR3 or —NR3 wherein R3 represents a steroidal derivative. The invention also concerns in vitro and in vivo applications of these compositions.

Abstract: The invention concerns a composition containing stabilised particles of cationic transfection agent(s)/nucleic acid complexes characterised in that it includes besides said transfection agent and nucleic acid at least a non-ionic surfactant in sufficient amount for preventing the aggregation of the particles in course of time. In a preferred embodiment, the surfactant is a polyoxyalkylene or a derivative thereof.

Abstract: The invention relates to a pharmaceutical composition which combines a tetrafunctional copolymer with a nucleic acid, said copolymer having formula I (namely a poloxamine), and preferably taking the form of one of the cationic mineral or organic salts thereof. The inventive composition can be used to improve in vivo gene transfer.

Abstract: The invention concerns a composition containing stabilized particles of cationic transfection agents/nucleic acid complexes characterized in that it includes besides said transfection agent and nucleic acid at least a non-ionic surfactant in sufficient amount for preventing the aggregation of the particles in course of time. In a preferred embodiment, the surfactant is a polyoxyalkylene or a derivative thereof.

Abstract: The invention concerns a composition containing stabilised particles of cationic transfection agent(s)/nucleic acid complexes characterised in that it includes besides said transfection agent and nucleic acid at least a non-ionic surfactant in sufficient amount for preventing the aggregation of the particles in course of time. In a preferred embodiment, the surfactant is a polyoxyalkylene or a derivative thereof.

Abstract: The invention relates to a pharmaceutical composition comprising a polynucleotide and at least 2% (weight/volume), preferably 2 to 10%, of a nonionic copolymer of formula (I)OH(CH2CH2O)a(CH(CH3)CH2O)a(CH2CH2O)cH, in which a, b, and c are such that the polyoxypropylene portion has a molecular weight of between 1450 and 2050, and the polyoxyethylene portions constitute between 75 and 85% (weight:weight) of the copolymer. The composition is preferably free of cationic lipid or of sodium phosphate. The copolymer is intended to improve the transfer of the polynucleotide into, or the expression of the polynucleotide in, eukaryotic cells. A typical example of a copolymer corresponding to formula (I) is F68. A composition according to the invention is in particular useful in the gene therapy, vaccination and immunotherapy fields.

Abstract: The invention concerns compositions comprising at least a nucleic acid and a mineral particle having an interchangeable foliate structure, the method for preparing them and their uses for in vivo, in vitro and/or ex vivo nucleic acid transfection.

Abstract: The invention concerns oligobenzimidazole derivatives capable of combining with nucleic acids and their uses including for transferring in vitro, in vivo, or ex vivo nucleic acids into cells or for visual display of nucleic acids administered by fluorescence.

Abstract: The invention concerns a novel agent for transferring nucleic acids into cells. Said agent is particularly characterised in that it comprises one or several disulphide bonds sensitive to reducing conditions. The invention also concerns compositions comprising such an agent for transferring in vivo, ex vivo or in vitro nucleic acids of interest into different cell types.